Pages
- Why RoslinCT
- Sustainability
- Training Academy
- Clinical & Commercial Manufacturing
- Process & Analytical Development
- Supply Chain & Logistics
- Quality & Regulatory Compliance
- Manufacturing Science & Technology
- cGMP iPSCs
- Privacy Policy
- Terms of Use
- Careers
- Facilities
- Services
- Home
- Insights
- Contact
- About
Posts by category
- Category: Blog
- The Build Versus Buy Decision
- Tackling the Cell Therapy Supply Chain
- RoslinCT Boston’s (former Lykan Bio) State-of-the-Art, Purpose-Built Cell Therapy Facility
- A Checklist for a Successful Cell Therapy Tech Transfer
- Four Keys to Reducing Variability in the Cell Therapy Process
- Insights about London Climate Action Week
- RoslinCT Blog Series: Scientific Advisory Board Perspectives
- Category: News
- RoslinCT Appoints Alexandra Brownfield as Head of Business Development
- RoslinCT Appoints Lee Warren as Chief Financial Officer
- RoslinCT continues its growth plans by expanding its operations at Edinburgh Technopole
- RoslinCT Announces the Appointment of Peter Coleman as CEO
- GHO Capital invests in RoslinCT, a leading cell therapy CDMO
- State-of-the-art manufacturing facility opens in Scottish capital
- RoslinCT announces the establishment of a Cell and Gene Training Academy
- RoslinCT and Lykan Bioscience announce that the MHRA has granted an MIA License for their cGMP Manufacturing facilities in Edinburgh, UK
- Life Sciences in Scotland: How Edinburgh Technopole is Driving Innovation
- RoslinCT Boston (former Lykan Bioscience) Welcomes Jay Blackington as Head of People and Culture
- RoslinCT Announces the Appointment of Dr. Derek Hei to its Scientific Advisory Board
- RoslinCT and Lykan Bioscience Combine to Create Leading Advanced Cell Therapy CDMO
- RoslinCT Boston Appoints Dean J. Morris, as Chief Operations Officer
- RoslinCT and Lykan Bioscience Announce the Establishment of a Scientific Advisory Board
- RoslinCT to Present at 2023 Cell & Gene Meeting on the Mesa
- RoslinCT Boston (former Lykan Bioscience) Appoints Barbara Ressler, Ph.D. as Vice President, Manufacturing Process Sciences
- Ian McCubbin receives Peter Dunnill award at bioProcessUK
- RoslinCT and Lykan Bioscience Announce the Appointment of Dr. Michael Mendicino to its Scientific Advisory Board
- RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration
- RoslinCT and Lykan Bioscience Announce the Addition of Six cGMP Suites to Meet Growing Demand
- RoslinCT to manufacture first-ever US FDA approved CRISPR-based gene therapy CASGEVY™ (exagamglogene autotemcel)
- RoslinCT and Lykan Bioscience Announce Integration to Establish Global Advanced Cell and Gene Therapy CDMO Service Offerings
- Governor Healey Highlights Life Sciences Investments from Mass Leads Act in Worcester and Hopkinton
- Category: Resources
- [EBOOK] Build Vs. Buy: A Critical Calculation for Cell Therapy Innovators
- [Q&A] Navigating Cell Therapy Supply Chain Challenges
- [EBOOK] Key Considerations for a Successful Cell Therapy Tech Transfer
- Industry 4.0 and Advanced Manufacturing
- [WEBINAR] iPSC cell line development and manufacture for cell therapies
Team
- Dean Morris
- Derek Hei, Ph.D.
- Michael Mendicino, Ph.D.
- Michael Kalos, Ph.D.
- Margit Jeschke, Ph.D.
- Michael Chambers
- Kenneth LeClair, Ph.D.
- Christopher (CJ) Burnes
- Peter Crowley
- Geoffrey Hamilton-Fairley
- Alan MacKay
- Andrea Ponti
- Ian McCubbin
- Barbara Ressler
- Jay Blackington
- Kathy Burri
- Matthew Treon
- Sheli Streck
- Patrick Lucy
- Adam Liddle
- Callum Watson
- Lynda Brown
- Alexandra Brownfield
- Kevin Bruce
- Jane Fraser
- Lee Warren, FCA
- Peter Coleman